Bofutrelvir

• CAT Number: I032743
• CAS Number: 2103278-86-8
• Molecular Formula: C25H32N4O4
• Molecular Weight: 452.55
• Purity: ≥95%
• Synonyms: N-[(2S)-3-cyclohexyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1H-indole-2-carboxamide
• InChI: InChI=1S/C25H32N4O4/c30-15-19(13-18-10-11-26-23(18)31)27-24(32)21(12-16-6-2-1-3-7-16)29-25(33)22-14-17-8-4-5-9-20(17)28-22/h4-5,8-9,14-16,18-19,21,28H,1-3,6-7,10-13H2,(H,26,31)(H,27,32)(H,29,33)/t18-,19-,21-/m0/s1
• InChIKey: HPKJGHVHQWJOOT-ZJOUEHCJSA-N
• SMILES: C1CCC(CC1)CC(C(=O)NC(CC2CCNC2=O)C=O)NC(=O)C3=CC4=CC=CC=C4N3

Bofutrelvir (Cat No.: I032743) is a peptidomimetic protease inhibitor developed to target the 3C-like protease (3CLpro) of coronaviruses, including SARS-CoV-2. By inhibiting this essential viral enzyme, Bofutrelvir blocks viral replication and transcription, making it a promising antiviral candidate. Its mechanism of action and structural mimicry of natural substrates allow for high specificity and potency. Bofutrelvir is primarily used in virology research to explore therapeutic strategies against coronavirus infections and has potential as a lead compound for developing broad-spectrum antiviral agents.

Reference

[1]. Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020 Sep 1;30(17):127377.
[Content Brief]

[2]. Shang W, et al. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antiviral Res. 2022 Dec;208:105450.
[Content Brief]